4D Molecular Therapeutics Stock
4D Molecular Therapeutics’ mission is to design and develop transformative gene therapy products using our proprietary.
About 4D Molecular Therapeutics Stock
4D Molecular Therapeutics, we are unlocking the full potential of the gene therapy field. Our customized AAV vectors can deliver genes to any cell in the body to eradicate disease.
Funding History
| August 2015 | $7.0M |
|---|---|
| September 2017 | $3.0M |
Management
Co-Founder
David Schaffer
COO
Anthony Davies
Co-Founder, President & CEO
David Kirn
Press
Roche boosts its gene therapy game, expanding partnership with 4D Molecular Therapeutics
Endpoints News - May, 1 2018
4DMT and ROCHE Expand Ophthalmology Partnership to Develop and Commercialize Multiple AAV Gene Therapy ...
Business Wire (press release) - Apr, 30 2018
4D Molecular Therapeutics Receives $3 Million Follow-On Funding from Cystic Fibrosis Foundation Therapeutics for ...
Business Wire (press release) - Sep, 19 2017
Other Companies
EquityZen does not have an affiliation with, formal relationship with, or endorsement from 4D Molecular Therapeutics or any companies feature above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
